Article: The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
The Journal of pharmacology and experimental therapeutics
2007 Volume 320, Issue 2, Page(s) 552–558
Abstract: There is a substantial body of evidence indicating that beta-amyloid peptides (Abeta) are critical factors in the onset and development of Alzheimer's disease (AD). One strategy for combating AD is to reduce or eliminate the production of Abeta through ... ...
| Abstract | There is a substantial body of evidence indicating that beta-amyloid peptides (Abeta) are critical factors in the onset and development of Alzheimer's disease (AD). One strategy for combating AD is to reduce or eliminate the production of Abeta through inhibition of the gamma-secretase enzyme, which cleaves Abeta from the amyloid precursor protein (APP). We demonstrate here that chronic treatment for 3 months with 3 mg/kg of the potent, orally bioavailable and brain-penetrant gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)-sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) attenuates the appearance of amyloid plaques in the Tg2576 mouse. These reductions in plaques were also accompanied by a decrease in the level of reactive gliosis. The morphometric and histological measures agreed with biochemical analysis of Abeta(40) and Abeta(42) in the cortex. Interestingly, the volume of the plaques across treatment groups did not change, indicating that reducing Abeta levels does not significantly alter deposit growth once initiated. Furthermore, we demonstrate that these beneficial effects can be achieved without causing histopathological changes in the ileum, spleen, or thymus as a consequence of blockade of the processing of alternative substrates, such as the Notch family of receptors. This indicates that in vivo a therapeutic window between these substrates seems possible--a key concern in the development of this approach to AD. An understanding of the mechanisms whereby MRK-560 shows differentiation between the APP and Notch proteolytic pathway of gamma-secretase should provide the basis for the next generation of gamma-secretase inhibitors. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Alzheimer Disease/drug therapy ; Alzheimer Disease/metabolism ; Alzheimer Disease/pathology ; Amyloid Precursor Protein Secretases/antagonists & inhibitors ; Amyloid beta-Peptides/metabolism ; Amyloid beta-Protein Precursor/antagonists & inhibitors ; Amyloid beta-Protein Precursor/metabolism ; Animals ; Brain/drug effects ; Brain/pathology ; Female ; Male ; Mice ; Protease Inhibitors/pharmacology ; Receptors, Notch/antagonists & inhibitors ; Receptors, Notch/metabolism ; Sulfonamides/pharmacology ; Sulfones/pharmacology | |||||
| Chemical Substances | Amyloid beta-Peptides ; Amyloid beta-Protein Precursor ; MRK 560 ; Protease Inhibitors ; Receptors, Notch ; Sulfonamides ; Sulfones ; Amyloid Precursor Protein Secretases (EC 3.4.-) | |||||
| Language | English | |||||
| Publishing date | 2007-02 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 3106-9 | |||||
| ISSN | 1521-0103 ; 0022-3565 | |||||
| ISSN (online) | 1521-0103 | |||||
| ISSN | 0022-3565 | |||||
| DOI | 10.1124/jpet.106.114330 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uf I Zs.40: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.